Swiss data analytics company SOPHiA Genetics SAis integrating a new radiomics technology to enhance its artificial intelligence (AI) platform, used already for analyzing genomic data from liquid biopsy tests in oncology. The radiomics capabilities were developed through a 10-year research project into mechanistic and mathematical modelling led by mathematics professor Thierry Colin at the INP research center in Bordeaux, France.
"The idea is to use radiology images with machine-learning techniques to predict the evolution of cancer tumors," Tarik Dlala, SOPHiA Genetics' VP of marketing told Medtech Insight